Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease

Bibliography

• El Meguid NA, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005;365:331-40
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. US Renal Data System, USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2006
   Google Scholar
• Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010-9
   PubMed Web of Science ®Google Scholar
• Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002;13:1307-20
   PubMed Web of Science ®Google Scholar
• Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-48
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Block G, Humphreys MH, et al. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 2004;15:442-53
   PubMed Web of Science ®Google Scholar
• Suliman ME, Barany P, Kalantar-Zadeh K, et al. Homocysteine in uraemia – a puzzling and conflicting story. Nephrol Dial Transplant 2005;20:16-21
   PubMedGoogle Scholar
• Wrone EM, Hornberger JM, Zehnder JL, et al. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004;15:420-6
   PubMed Web of Science ®Google Scholar
• Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007;298:1163-70
   PubMed Web of Science ®Google Scholar
• Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004;291:451-9
   PubMed Web of Science ®Google Scholar
• Stenvinkel P. Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif 2001;19:53-61
   PubMed Web of Science ®Google Scholar
• Bellomo G, Lippi G, Saronio P, et al. Inflammation, infection and cardiovascular events in chronic hemodialysis patients: a prospective study. J Nephrol 2003;16:245-51
   PubMed Web of Science ®Google Scholar
• Haubitz M, Brunkhorst R. C-reactive protein and chronic Chlamydia pneumoniae infection – long-term predictors for cardiovascular disease and survival in patients on peritoneal dialysis. Nephrol Dial Transplant 2001;16:809-15
   PubMed Web of Science ®Google Scholar
• Slade GD, Offenbacher S, Beck JD, et al. Acute-Phase Inflammatory response to periodontal disease in the US population. J Dent Res 2000;79:49-57
   PubMed Web of Science ®Google Scholar
• Feldman AM, Combes A, Wagner D, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000;35:537-44
   PubMed Web of Science ®Google Scholar
• Heinrich J, Schulte H, Schonfeld R, et al. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost 1995;73:374-9
   PubMed Web of Science ®Google Scholar
• Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999;353:1838-42
   PubMed Web of Science ®Google Scholar
• Pecoits-Filho R, Heimburger O, Barany P, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003;41:1212-8
   PubMed Web of Science ®Google Scholar
• Arizono K, Nomura K, Motoyama T, et al. Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis. Blood Purif 2004;22(Suppl 2):26-9
   PubMed Web of Science ®Google Scholar
• Ayus JC, Mizani MR, Achinger SG, et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 2005;16:2778-88
   PubMed Web of Science ®Google Scholar
• Gesualdo L, Pertosa G, Grandaliano G, Schena FP. Cytokines and bioincompatibility. Nephrol Dial Transplant 1998;13:1622-6
   PubMed Web of Science ®Google Scholar
• Malaponte G, Bevelacqua V, Fatuzzo P, et al. IL-1beta, TNF-alpha and IL-6 release from monocytes in haemodialysis patients in relation to dialytic age. Nephrol Dial Transplant 2002;17:1964-70
   PubMed Web of Science ®Google Scholar
• Memoli B, Minutolo R, Bisesti V, et al. Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes. Am J Kidney Dis 2002;39:266-73
   PubMed Web of Science ®Google Scholar
• Panichi V, Tetta C, Rindi P, et al. Plasma C-reactive protein is linked to backfiltration associated interleukin-6 production. ASAIO J 1998;44:M415-7
   PubMed Web of Science ®Google Scholar
• Schindler R, Beck W, Deppisch R, et al. Short bacterial DNA fragments: detection in dialysate and induction of cytokines. J Am Soc Nephrol 2004;15:3207-14
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147
   PubMed Web of Science ®Google Scholar
• Bologa RM, Levine DM, Parker TS, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998;32:107-14
   PubMed Web of Science ®Google Scholar
• Ikizler TA, Wingard RL, Harvell J, et al. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Kidney Int 1999;55:1945-51
   PubMed Web of Science ®Google Scholar
• Pifer TB, McCullough KP, Port FK, et al. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 2002;62:2238-45
   PubMed Web of Science ®Google Scholar
• Racki S, Zaputovic L, Mavric Z, et al. C-reactive protein is a strong predictor of mortality in hemodialysis patients. Ren Fail 2006;28:427-33
   PubMed Web of Science ®Google Scholar
• Zimmermann J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-58
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Kopple JD, Humphreys MH, Block G. Comparing outcome predictability of markers of malnutrition–inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant 2004;19:1507-19
   PubMed Web of Science ®Google Scholar
• Kaysen GA, Dubin JA, Muller HG, et al. Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int 2002;61:2240-9
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340:115-26
   PubMed Web of Science ®Google Scholar
• Gottlieb AB. Tumor necrosis factor blockade: mechanism of action. J Investig Dermatol Symp Proc 2007;12:1-4
   PubMed Web of Science ®Google Scholar
• Nikas SN, Drosos AA. Onercept. Serono. Curr Opin Investig Drugs 2003;4:1369-76
   PubMedGoogle Scholar
• Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50
   PubMed Web of Science ®Google Scholar
• Knight R. IMiDs: a novel class of immunomodulators. Semin Oncol 2005;32:S24-30
   PubMed Web of Science ®Google Scholar
• Kiely PD, Gillespie KM, Oliveira DB. Oxpentifylline inhibits tumor necrosis factor-alpha mRNA transcription and protects against arthritis in mercuric chloride-treated brown Norway rats. Eur J Immunol 1995;25:2899-906
   PubMed Web of Science ®Google Scholar
• Dubost JJ, Soubrier M, Ristori JM, et al. An open study of the anti-TNF alpha agent pentoxifylline in the treatment of rheumatoid arthritis. Rev Rhum Engl Ed 1997;64:789-93
   PubMedGoogle Scholar
• Kiely PD, Johnson D, Bourke BE. An open study of oxpentifylline in early rheumatoid arthritis. Br J Rheumatol 1998;37:1033-5
   PubMedGoogle Scholar
• Maksymowych WP, Vina-Zubieta A, Luong MH, Russell AS. An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. J Rheumatol 1995;22:625-9
   PubMed Web of Science ®Google Scholar
• Baharav E, Bar-Yehuda S, Madi L, et al. Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J Rheumatol 2005;32:469-76
   PubMed Web of Science ®Google Scholar
• Sajjadi FG, Takabayashi K, Foster AC, et al. Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. J Immunol 1996;156:3435-42
   PubMed Web of Science ®Google Scholar
• van Troostenburg AR, Clark EV, Carey WD, et al. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. Int J Clin Pharmacol Ther 2004;42:534-42
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu J, Levin J, et al. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpho linecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. J Pharmacol Exp Ther 2004;309:348-55
   PubMed Web of Science ®Google Scholar
• Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993;54:167-227
   PubMed Web of Science ®Google Scholar
• Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest 1990;85:1694-7
   PubMed Web of Science ®Google Scholar
• Cunnane G, Madigan A, Murphy E, et al. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology (Oxford) 2001;40:62-9
   PubMed Web of Science ®Google Scholar
• Smith RJ, Chin JE, Sam LM, Justen JM. Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness. Arthritis Rheum 1991;34:78-83
   PubMed Web of Science ®Google Scholar
• Yang BB, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther 2003;74:85-94
   PubMed Web of Science ®Google Scholar
• Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 2003;9:47-52
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol 2004;4:378-85
   PubMed Web of Science ®Google Scholar
• Rudolphi K, Gerwin N, Verzijl N, et al. Pralnacasan, an inhibitor of interleukin-1[beta] converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage 2003;11:738-46
   PubMed Web of Science ®Google Scholar
• Siegmund B. Interleukin-1[beta] converting enzyme (caspase-1) in intestinal inflammation. Biochem Pharmacol 2002;64:1-8
   PubMed Web of Science ®Google Scholar
• Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993;54:1-78
   PubMed Web of Science ®Google Scholar
• Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol 1998;16:249-84
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-74
   PubMed Web of Science ®Google Scholar
• Foy TM, Aruffo A, Bajorath J, et al. Immune regulation by CD40 and its ligand GP39. Ann Rev Immunol 1996;14:591-617
   PubMed Web of Science ®Google Scholar
• Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Ann Rev Immunol 1996;14:233-58
   PubMed Web of Science ®Google Scholar
• Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998;338:1813-21
   PubMed Web of Science ®Google Scholar
• Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996;381:434-8
   PubMed Web of Science ®Google Scholar
• Quattrocchi E, Dallman MJ, Feldmann M. Adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritis. Arthritis Rheum 2000;43:1688-97
   PubMed Web of Science ®Google Scholar
• Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140-74
   PubMedGoogle Scholar
• Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003;48:2146-54
   PubMed Web of Science ®Google Scholar
• Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81
   PubMed Web of Science ®Google Scholar
• Cambridge G, Leandro MJ, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006;54:3612-22
   PubMed Web of Science ®Google Scholar
• Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:262-8
   PubMed Web of Science ®Google Scholar
• Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006;173:180-7
   PubMed Web of Science ®Google Scholar
• Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006;54:2970-82
   PubMed Web of Science ®Google Scholar
• Kamar N, Faguer S, Esposito L, et al. Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports. Clin Nephrol 2007;67:250-4
   PubMed Web of Science ®Google Scholar
• Milovanova SI, Lopatkina TN, Kozlovskaia LV, Krasnova TN. Monoclonal antibodies to B-lymphocytes (rituximab) in the treatment of HCV-associated severe cryoglobulinemic glomerulonephritis [in Russian]. Ter Arkh 2007;79:69-72
   PubMedGoogle Scholar
• Ponticelli C. New therapies for lupus nephritis. Clin J Am Soc Nephrol 2006;1:863-8
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Chiurchiu C, Abbate M, et al. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol 2006;1:738-48
   PubMed Web of Science ®Google Scholar
• Smith RJ, Alexander J, Barlow PN, et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 2007;18:2447-56
   PubMed Web of Science ®Google Scholar
• Waldmann TA, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Ann Rev Immunol 1999;17:19-49
   PubMed Web of Science ®Google Scholar
• Baslund B, Tvede N, Danneskiold-Samsoe B, et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum 2005;52:2686-92
   PubMed Web of Science ®Google Scholar
• Gracie JA, Forsey RJ, Chan WL, et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999;104:1393-401
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Interleukin-18 and the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 2004;30:417-34, ix
   PubMed Web of Science ®Google Scholar
• Marx N, Sukhova G, Murphy C, et al. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998;153:17-23
   PubMed Web of Science ®Google Scholar
• Ricote M, Huang J, Fajas L, et al. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 1998;95:7614-9
   PubMed Web of Science ®Google Scholar
• Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Ann Rev Immunol 1994;12:141-79
   PubMed Web of Science ®Google Scholar
• Baeuerle PA. IkappaB-NF-kappaB structures: at the interface of inflammation control. Cell 1998;95:729-31
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71
   PubMed Web of Science ®Google Scholar
• Grilli M, Chiu JJ, Lenardo MJ. NF-kappa B and Rel: participants in a multiform transcriptional regulatory system. Int Rev Cytol 1993;143:1-62
   PubMed Web of Science ®Google Scholar
• Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-6
   PubMedGoogle Scholar
• Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82
   PubMed Web of Science ®Google Scholar
• Su CG, Wen X, Bailey ST, et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999;104:383-9
   PubMed Web of Science ®Google Scholar
• Minamikawa J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998;83:1818-20
   PubMed Web of Science ®Google Scholar
• Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001;86:3452-6
   PubMed Web of Science ®Google Scholar
• Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004;89:2728-35
   PubMed Web of Science ®Google Scholar
• Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-84
   PubMed Web of Science ®Google Scholar
• Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003;42:1757-63
   PubMed Web of Science ®Google Scholar
• Wong TY, Szeto CC, Chow KM, et al. Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 2005;46:713-9
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
   PubMed Web of Science ®Google Scholar
• Albert JM, Tentori F, Young EW, et al. Rosiglitazone is associated with increased mortality among diabetic HD patients in the US DOPPS. J Am Soc Nephrol 2007;18:44A
   Google Scholar
• Moncada S, Ferreira SH, Vane JR. Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature 1973;246:217-9
   PubMed Web of Science ®Google Scholar
• Diaz-Gonzalez F, Gonzalez-Alvaro I, Campanero MR, et al. Prevention of in vitro neutrophil-endothelial attachment through shedding of L-selectin by nonsteroidal antiinflammatory drugs. J Clin Invest 1995;95:1756-65
   PubMed Web of Science ®Google Scholar
• Amin AR, Vyas P, Attur M, et al. The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase. Proc Natl Acad Sci USA 1995;92:7926-30
   PubMed Web of Science ®Google Scholar
• Lu X, Xie W, Reed D, et al. Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts. Proc Natl Acad Sci USA 1995;92:7961-5
   PubMed Web of Science ®Google Scholar
• Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-5
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230-5
   PubMed Web of Science ®Google Scholar
• Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70
   PubMed Web of Science ®Google Scholar
• Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002;106:1447-52
   PubMed Web of Science ®Google Scholar
• McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015-21
   PubMed Web of Science ®Google Scholar
• Nissen SE. High-dose statins in acute coronary syndromes: not just lipid levels. JAMA 2004;292:1365-7
   PubMed Web of Science ®Google Scholar
• Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7:687-92
   PubMed Web of Science ®Google Scholar
• Frenette PS. Locking a leukocyte integrin with statins. N Engl J Med 2001;345:1419-21
   PubMed Web of Science ®Google Scholar
• Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6:1399-402
   PubMed Web of Science ®Google Scholar
• Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 2003;S207-10
   Google Scholar
• Fellstrom BC, Holdaas H, Jardine AG. Why do we need a statin trial in hemodialysis patients? Kidney Int Suppl 2003:S204-6
   Google Scholar
• Gullestad L, Aukrust P, Ueland T, et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 1999;34:2061-7
   PubMed Web of Science ®Google Scholar
• Tsutamoto T, Wada A, Maeda K, et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol 2000;35:714-21
   PubMed Web of Science ®Google Scholar
• Stenvinkel P, Andersson P, Wang T, et al. Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure? J Intern Med 1999;246:503-7
   PubMed Web of Science ®Google Scholar
• Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629-36
   PubMed Web of Science ®Google Scholar
• Ferramosca E, Burke S, Chasan-Taber S, et al. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005;149:820-5
   PubMed Web of Science ®Google Scholar
• Yamada K, Fujimoto S, Tokura T, et al. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients. Ren Fail 2005;27:361-5
   PubMed Web of Science ®Google Scholar
• Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-24
   PubMed Web of Science ®Google Scholar
• Nadra I, Mason JC, Philippidis P, et al. Proinflammatory activation of macrophages by basic calcium phosphate crystals via protein kinase C and MAP kinase pathways: a vicious cycle of inflammation and arterial calcification? Circ Res 2005;96:1248-56
   PubMed Web of Science ®Google Scholar
• Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1041-3
   PubMed Web of Science ®Google Scholar
• Tyrrell DJ, Horne AP, Holme KR, et al. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999;46:151-208
   PubMedGoogle Scholar
• Gaffney A, Gaffney P. Rheumatoid arthritis and heparin. Br J Rheumatol 1996;35:808-9
   PubMedGoogle Scholar
• Bowler SD, Smith SM, Lavercombe PS. Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am Rev Respir Dis 1993;147:160-3
   PubMed Web of Science ®Google Scholar
• Dwarakanath AD, Yu LG, Brookes C, et al. ‘Sticky’ neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Gut 1995;37:585-8
   PubMed Web of Science ®Google Scholar
• Salas A, Sans M, Soriano A, et al. Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism. Gut 2000;47:88-96
   PubMed Web of Science ®Google Scholar
• Lever R, Hoult JR, Page CP. The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leucocytes to vascular endothelium in vitro. Br J Pharmacol 2000;129:533-40
   PubMed Web of Science ®Google Scholar
• Bossola M, Muscaritoli M, Tazza L, et al. Malnutrition in hemodialysis patients: what therapy? Am J Kidney Dis 2005;46:371-86
   PubMed Web of Science ®Google Scholar
• Lambert CP, Sullivan DH, Evans WJ. Effects of testosterone replacement and/or resistance training on interleukin-6, tumor necrosis factor alpha, and leptin in elderly men ingesting megestrol acetate: a randomized controlled trial. J Gerontol A Biol Sci Med Sci 2003;58:165-70
   PubMed Web of Science ®Google Scholar
• Mantovani G, Maccio A, Lai P, et al. Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. Crit Rev Oncog 1998;9:99-106
   PubMed Web of Science ®Google Scholar
• Mantovani G. Does megestrol acetate down-regulate interleukin-6 in patients? Support Care Cancer 2002;10:566-7
   PubMed Web of Science ®Google Scholar
• Yeh SS, Wu SY, Levine DM, et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. J Gerontol A Biol Sci Med Sci 2001;56:M48-54
   PubMed Web of Science ®Google Scholar
• Boccanfuso JA, Hutton M, McAllister B. The effects of megestrol acetate on nutritional parameters in a dialysis population. J Ren Nutr 2000;10:36-43
   PubMedGoogle Scholar
• Burrowes JD, Bluestone PA, Wang J, Pierson RN Jr. The effects of moderate doses of megestrol acetate on nutritional status and body composition in a hemodialysis patient. J Ren Nutr 1999;9:89-94
   PubMed Web of Science ®Google Scholar
• Rammohan M, Kalantar-Zadeh K, Liang A, Ghossein C. Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients. J Ren Nutr 2005;15:345-55
   PubMed Web of Science ®Google Scholar
• Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000;356:1213-8
   PubMed Web of Science ®Google Scholar
• Yang CC, Hsu SP, Wu MS, et al. Effects of vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced oxidative stress. Kidney Int 2006;69:706-14
   PubMed Web of Science ®Google Scholar
• Tepel M, van der GM, Statz M, et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003;107:992-5
   PubMed Web of Science ®Google Scholar
• Parthasarathy S, Santanam N, Ramachandran S, Meilhac O. Oxidants and antioxidants in atherogenesis. An appraisal. J Lipid Res 1999;40:2143-57
   PubMed Web of Science ®Google Scholar
• Wolin MS. Interactions of oxidants with vascular signaling systems. Arterioscler Thromb Vasc Biol 2000;20:1430-42
   PubMed Web of Science ®Google Scholar
• Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965;58:295-300
   PubMed Web of Science ®Google Scholar